vasu needs B.Pharm

We are the leading herbal manufacturers and we have openings in the following.

2 posts Production Chemist
2 posts Quality Assurance Chemist
1 posts Quality Control Chemist

Fresh or Experinced B.Pharma Candidates can apply.

Send in your updated C.V. on following address or contect me on my mobile no.

Arvind Panchal
Executive - Production
Vasu healthcare Pvt.Ltd.
896/A , G.I.D.C.
Makarpura
Vadodara - 390010
Ph. 0265 - 2657701/02/03
Mob.9898227659

AN OPEN INTERVIEW ON 14th August for B.Phar/D.Pharm

Dear candidate,

We have received your candidature to work with Ayurlab herbals Pvt. Ltd.. Please fill the attached format & send us back as soon as possible.

You can send us the filled format through e-mail at: ayurlab@rediffmail.com & by post or personally at our Corporate office.

WE HAVE ORGANIZED AN OPEN INTERVIEW ON 14th August 2010 AT OUR CORPORATE OFFICE (BARODA) FROM 10:00 AM TO 1:00 PM.
YOU ARE REQUESTED TO COME FOR THE SAME ALONG WITH ALL NECESSARY DOCUMENTS.

Please confirm.

With Best Wishes,
Hetal
(H.R. & Admin. Dept.)

Corporate office:
AYURLAB HERBALS PVT. LTD.
310, 2nd floor kale chambers,
Raopura
Vadodara.
Phone No. 0265 2425413
Fax: 0265 2416253





--
I/C
Pharmaceutical Training and placement Cell(PTP cell),
Institute of Ayurvedic Pharmaceutical Sciences,
Gujarat Ayurved University,
Jamnagar-361005
phone:0288 2555746
http://ptpcell.blogspot.com/

job alert for B.Pharm

Production Pharmacist - Freshers Can Apply
3 Opening(s)
ALARSIN Pharmaceuticals

Summary
Experience:
0 - 3 Years
Location: Surat
Compensation: As per Industry Standards
Education:UG - B.Pharma - Pharmacy PG - Post Graduation Not Required

Role:Production Mgr
Functional Area: Production, Maintenance, Quality
Posted Date: 02 Aug
Desired Candidate Profile
Should be B. Pharm with 0-4 yrs. exp. with good exposure in Ayurvedic pharma co., Well versed with concepts of Mfg/ Pkg/ Checking Process Validation.
Job Description
To look after manufacturing of ayurvedic medicine manufacturing plant.
Keywords: ayurvedic pharmacheticals pharma ayurved production pharmacist
Company Profile
Over 50 years ago, ALARSIN set up 'Manthan' its research division to develop original research products based on Ayurvedic drugs in the light of ancient and modern medical knowledge to fill the need for safe, simple and reliable treatments.
With the encouragement and co-operation of quality Doctors, ALARSIN has been able to contribute original Research products backed by extensive clinical experience and modern research trials at the highest levels.

A number of research papers and articles based on modern Clinical, Pharmacological, Bacteriological and Experimental studies on ALARSIN’S research products have been presented before Medical, Dental and Veterinary Conferences and published in recognized Medical Journals in India and abroad.
Contact Details
Company Name:
ALARSIN Pharmaceuticals
Website:
http://www.alarsin.com
Executive Name:
Mr.Jayesh V Mehta
Address:
ALARSIN Pharmaceuticals
Plot No. A-2/1, Road No.1, Udhana Udhyog Nagar,
UDhna,Surat
SURAT,Gujarat,India 394210
Email Address:
udhna@alarsin.com
Telephone:
91-261-2278235

Dear All,

It is happy to inform you one of the most dreamed company selected our Ap.,

now the Ap .has joined the Ayurvedic MNC this week,

want to know more...about the co. and our fellow Ap. to congratulate............(to request make a place/channel for us (Ap.) also!!!!!)

yes the name of co is Himalaya Healthcare,

Bangalore

the Ap. Prabhat verma joined this with week with handsome package......of till date......

so for whom...you are waiting...just ....find this fellow person in our online group and greet...him for his success...who knows he may award you the same with little more...

have a wondrful job jumping.....

A breakthrough placement

Dear Friends,

we initiate the this PTPCell with a view to enhance the opportunity for our Aps.

Now, we need to establish a channel/ lobby for our future as our strength day by day increasing,

the first /fresh entry always pain much requires sound efforts,

as a result of such a hard stuff we are about to announce first break through placement of an Ap. at most reputed Ayurvedic Co.,

The count down is on any time we may get best placement news ever,

keep visiting/follow us on our blog : http://ptpcell.blogspot.com for full details ,

we will announce full detail on our blog only

with best wishes

Ayurlab ,Halol requires D.Pharm/ B.Pharm (Ayu)

Dear Friends,

Ayurlab ,Halol requires D.Pharm/ B.Pharm (Ayu) freshers,

Dept: Production ,Q.C. lab, Store house

Rush your resume to us , we will forward the same

CCRAS requires Paramedical staff

Dear friends ,

please go through the attachment

CCRAS ,apex research council of Ayurved requires D.Pharm(Ayu) and B.pharm(Ayu) for the post of Pharmacist and Lab technician ,

the service is of regular govt. in nature ,with the benefits of central govt. norms,

so ,don`t wait it is a good opportunity for Dpharm in perticular to go for govt. job.

all the best

Hamdard launches JIGREEN for healthy liver

Hamdard (Wakf) Laboratories, recently unveiled ‘JIGREEN’, a clinically tested product for liver health. It is a 100 percent natural, unique multi-herb formulation, helps and ensuresoptimum liver function by protecting the liver against harmful toxins like drugs, alcohol, and contaminated food and water. It is developed on the principles of the unani system, JIGREEN is clinically tested for its efficacy in treatment of liver disorders like viral hepatitis, drug induced hepatitis and alcoholic liver disease.

JIGREEN is also an excellent general health supplement that helps detoxify the system, stimulate appetite, and promote strength and good health. A 200 ml syrup pack of JIGREEN is available at pharmacies across the country at a cost of Rs 70. Arshad Siddiqui, Chief Marketing Officer, Hamdard (Wakf) Laboratories said, “Liver diseases in India are on the rise. Alcohol abuse, tobacco smoking, and unhealthy eating habits have been the main reasons behind the rise of liver diseases. JIGREEN, a formulation of time tested herbs, protects the liver against harmful toxins and ensures healthy functioning of the liver.”

Hamdard has grown into an institution devoted to provide health to all through promotion and development of unani.

A premier pharmahouse with a nationalist inspiration and a total indigenous base, the company stands as a mission committed to serve the benefit the society. The company aims at touching life at various aspects of human welfare by way of imparting health education, conducting research on the therapeutics and drug of natural medicine, extending philanthropic services through the Hamdard National Foundation.

Building Big Pharma Brands

With an eye to become more visible to their customers, Indian pharma companies realise that they need to get into a major branding exercise, especially as attention shifts to the over the counter (OTC) sector.

The Indian pharmaceutical industry has emerged as one of the most attractive markets globally as its growth continues to outperform the growth of the global industry and particularly markets such as US and in the EU. According to the Ministry of Commerce, domestic investment in the pharma sector is estimated at $ 6.31 billion.

With intense competition, it is becoming more important to build an emotional bonding and a relationship of trust and comfort with the customer to ensure loyalty and hence consistent sales. Hence there is a need to differentiate a product from competition and establish a positive image of the drug and the company in the eyes of the customer.

In fact, a distinct brand image is the best security a company is likely to have against competition. Therefore companies are spending more and money with an extensive effort on brand building. This is seen mostly in pharma companies which have over-the-counter (OTC) products like Dabur, Paras, P&G, J&J, GSK, Pfizer, Emami , Piramal, Ranbaxy and Heinz are some of the leading players in the Indian OTC segment. Overall, well renowned brands like Revital (Ranbaxy), Smyle, Glycodin (Alembic), Crocin (GSK), Moov, Ring Guard, Itch Guard, D’Cold, Krack (Paras Pharma), Lactocalamine, Supractive, i-pill (Piramal), Digene (Abbott), Gelusil (Pfizer), Sugar free (Zydus),etc. have succeeded in establishing customer loyalty and positive brand images. The importance of branding in the pharma industry is also evident from the several brand acquisitions in the recent years. The fact that 25 percent of Pfizer's revenues come from one brand (Lipitor) has often been cited as the importance of branding.

“While no amount of marketing can yield profits for a failed product,”explains Hitesh Gajaria, Executive Director – KPMG, “it is also true that attractive graphics and design, good packaging play a role in prescription medication, as there are a large number of products that the physician is exposed to on a daily basis. The sustainable growth is driven by strong socio-economic drivers luring several domestic companies, many of which have been predominantly export market-focused, to expand their presence and build a stronger foothold in the Indian market. “

Gajaria emphasises on thrust of the pharma OTC branding in the current scenario, “A brand can be termed successful in the pharma sector if doctors are motivated to prescribe it. It may be important to link a desired emotion with the brand because it is often observed that the best way to grab attention is by evoking an emotional response. Most importantly, it is vital that the product should be efficacious and able to deliver.”

Shakti Prasad Chakraborty, President of India Region Formulation Lupin shares Lupin's branding strategy and highlights the product relevance in the market, “Lupin’s flagship brand 'Suprax' in the US or 'Tonact' in India will still resonate with paediatricians and patients alike, so it is important to us to form this association. Branding pharma products is much like any other brand-building initiative. The goal is to make your own brand distinguishable against products that are becoming increasingly similar in the decision-maker’s mind. However, there are some peculiarities to branding in the pharma industry.”

Building brand equity

"A decade ago the product brand used to be the strongest point of recall but we have observed a gradual move towards association with the corporate brand name. Pharma companies and its products are not consumer goods and the demand for most of them is need-based so the emphasis on both the corporate and product (identity) is that much stronger" - Shakti Prasad Chakraborty President of India Region Formulation Lupin

"OTC products are comparatively cheap as compared to ethical branded products. In today's scenario, the whole world is looking for reduction of medicine cost and all big Indian pharma companies" - Vinod Chitalia Chief Executive Officer Lifeline Industries

"Branding exercises for pharma products in India do not have any specified guidelines. there are regulations for marketing. Currently, there is no specific law which prohibits the advertising of prescription drugs although industry practice is not to advertise prescription-only drugs" - Hitesh Gajaria Executive Director KPMG

The differentiating factor is that pharma companies deal with an intermediary, ie the doctor, controlling what consumers might or might not end up purchasing . So most branding activities in the Industry do take that into account and most marketing and communication programmes are focused on building brand equity with the doctor, reasons Chakraborty. “If you are marketing the fifth or the 15th drug in a therapy class, the task at hand becomes all the more complex and difficult to make sure doctors remember your brand,” he says.

According to Chakraborty, “Doctors and patients both tend to recall of the corporate brand and then drug name. A decade ago the product brand used to be the strongest point of recall but we have observed a gradual move towards association with the corporate brand name. Pharma companies and its products are not consumer goods and the demand for most of them is need-based so the emphasis on both the corporate and product (identity) is that much stronger. Moreover in some markets globally, beyond patent expiry, drugs compete on price alone. Pharmacists can substitute cheaper generic products for name brands on a patient's script (unless otherwise stipulated by the prescribing doctor). Yet even if the product dies, the brand still lives. It is not possible to roll the brand over to a new product unless it is a reformulation, but you can keep certain elements of previous brands.”

Vinod Chitalia, Chief Executive Officer Lifeline Industries remarks positively on OTC branding through an explanation of successful companies name, “OTC products are comparatively cheap as compared to ethical branded products. In today's scenario, the whole world is looking for reduction of medicine cost and all big Indian pharma companies like Ranbaxy, Cipla, Wockhardt, etc,have developed separate OTC generic divisions. MNC’s like Novartis, Abbott are also trying to enter the OTC generic market in a big way considering the percentage sale of OTC in the long run.”

S C Sehgal, Chairman of the Ozone Group of company says, “OTC branding helps the company earn greater revenue and also there is a large customer base in today’s market. OTC brands are well known by the consumers and people do not have to have a doctor’s prescription for these medicines. They have been delivering high on consumers requirements and therefore have an impression in the minds of the consumer. People prefer more usage of these products and thereby helping the company to earn more revenues.”

Corporate expansion is a strategic decision and should be related to a firm's objectives and mission. Various critical factors that need to be considered are market risk, returns from a new set-up, opportunity cost, resource availability, dominant market, etc. Hence, marketing strategy that should be considered during an expansion plan should be able to relate to the new target customer base and the market. This strategy can be devised only after a thorough analysis of the new market and customer base. Hence, while devising such a strategy, it is important to consider several factors such as demand for the product, brand image of the company, spending capacity of the new market customer base, etc.

Smitesh Shah, Chairman and Managing Director, Calyx Chemicals and Pharmaceuticals Ltd, gives details on branding expenditure saying, “The brand spend always differs from company to company and its products reach, however most companies in the growth phase would need to budget for a minimum of 25-30 percent of sales as branding cost. There’s a huge opportunity as the market is substantially under-penetrated for OTC products. For a country of our size, a $ 1.9 billion market is tiny to say the least. It would need to be a mix of all as finally each one of these affects the corporate identity in its own unique way. However, from a domestic market perspective, the critical differentiation continues to be branding and marketing skill sets.”

He further emphasises that besides investing in creation of global assets and brands ; investments in fixed assets expenditure like quality control and SHE (Safety, Health & Environment) are crucial and are the need of the hour.

“The corporate and product branding helps the company to sustain its market value by creating the brand in the doctors’ clinic and thereby increasing its visibility to the patient visiting the doctor and also to the doctor for prescribing the medicine. The pharma companies should opt for product branding as it pays you more as it leaves a mark in the mind of the consumer whenever he/ she visit the doctor. ,” adds Sehgal.

Gajaria says, “Sales of OTC medicines in India are forecast to increase from $ 2.14 billion in 2008 to $ 5.05 billion in 2014, representing a CAGR of 17.69 percent. According to AESGP data, leading OTC categories include vitamins and minerals, cough and cold, gastrointestinal medications, analgesics, dermatologicals and herbal medicines. However, many prescription (Rx) drugs can be purchased without prescription, which has meant that OTC switching is not actively promoted. Sales of vitamins and minerals generated 24.2 percent of the Indian OTC pharma market's value. Product branding is an effective technique of increasing the sales of a particular product. Effective product branding can establish the presence of the product in the market and create a positive image of its use and efficacy without any necessary holding to the company name.”

He further elaborates with an example that, “i- pill has very strong brand strength. Although the product was previously owned by Cipla and now belongs to Piramal Healthcare, it is still able to generate sales and has a hold on the emergency contraceptive market.”

Company	Measures taken
Allergen Inc	New entry in India- specialises in medications for infectious diseases
Novartis	In 2009, raised its stake in Novartis India . from 50.9percent to 76.4 percent
Pfizer	In 2009, increased stake in Pfizer India, from 41.2 percent to ~71 percent
Mylan Laboratories	Acquired Matrix Laboratories to strengthen generic presence
Daiichi Sankyo	Acquired Ranbaxy to strengthen generic presence
Sanofi Pasteur	Acquired Shantha Biotechnics via Mérieux Alliance

Foreign companies too, in recent years, are increasing their focus on India as a key market. Besides Abbot, which very recently did a multi-billion dollar deal to acquire the domestic formulations business of Piramal, the table below illustrates efforts of some other global pharma giants to increase their presence in India:

Kiran Das, General Manager - Exports and Herbals, Anglo-French Drugs & Industries further elaborates Gajaria's view commenting, “The pharma companies with its brands that have gained an OTC status (products that technically are to be dispensed only with prescription but have patients asking for them by brand name), due to usage over a long period of time, focus on bettering the brand image through various branding exercises. These companies also focus on the corporate branding at the retail and wholesaler front. The segments that have good support for OTC sales are vitamins, dermatological, analgesic, cough syrup and anti inflammatory. We can see lot of branding activities being carried out for these products. The focus of branding in these segments remains on doctors and retailers. Visibility and availability play an important role here.

Chitalia highlights the brand value of pharma products and brand loyality commenting that “In the pharma industry, a product is sold by brand name, it’s like a wine. Pharma industry enjoys royalty by way of brand value creation. All MNC's or big pharma companies earn their maximum top line and bottom line from the first few brands. It is seen from the sale of companies like Ranbaxy and Piramal Healthcare.” He predicts that, “In the coming six to eight months one more Indian pharma giant is about to follow a similar path. Hence Indian pharma companies want to develop brands which can sustain the company’s profitability forever.”

In fact, corporate branding initiatives impact individual product branding initiatives and need to go hand in hand, and can help organisations leverage their positive image on the retailer and patient front, this is one of the biggest reasons why pharma companies dealing with OTC products focus extensively on building corporate image. They do this with product branding followed by corporate branding through commercial advertisements in media. The focus is to highlight both the product and the corporate brand.

Joy Chatterjee, Manager - Product, Mankind Pharma , emphasises on brand image and its thrust in the competitive market. For Mankind Pharma a well known name in the OTC branding sphere, he says, “Branding is an extremely important marketing strategy in the Indian pharma Industry. It is important to build an emotional bonding and a relationship of trust with the customer to ensure loyalty and hence consistent sales. Indian market is highly fragmented and hence a distinct brand image will make brand equity.”

Some leading companies and their brands
Sr. No	Company	Product	Therapeutic use
1	Pfizer	Corex, Becosule	Cough Multi Vitamin
2	GlaxoSmithKline	Vicks Action 500, Crocin	Cough and cold Fever
3	Nicholas Piramal	i- pill	Emergency contraceptive
4	Ranbaxy	Revital	Energy and fatigue
5	Novartis	Voveran	Analgesic

Ethics of pharma marketing

"The focus on branding is getting higher as there is a general shift observed in the power of the consumer to directly take medication and seek alternatives when at the retailer's" - Kiran Das General Manager Exports and Herbals Anglo-French Drugs & Industries

"Branding and marketing would most certainly help a company to go a long way, however sustainable and profitable growth would largely come from continuous focus on quality" - Smitesh Shah Chairman and Managing Director Calyx Chemicals and Pharmaceuticals Ltd

"The Pharma companies should opt for product branding as it pays you more as it leaves a mark in the mind of the consumer whenever he/ she visit the doctor. Branding also helps in the visibility of the product and the company" - S C Sehgal Chairman of the Ozone Group of company

The major legislation for pharma regulation is the Drugs and Cosmetics Act, 1940 (DCA) and its subordinate legislation, the Drugs and Cosmetics Rules,1945 (DCR). Drug Prices Control Order, 1995, Drugs (Magic Remedies) Objectionable Advertisement Act, 1954 and Pharmacy Act, 1948 are other regulations which have a bearing on the pharma business in India. The legislations apply to the whole of India and to all categories of medicines, whether imported or manufactured in India. The legislation is regulated by the Central Government (Ministry of Health & Family Welfare) in New Delhi, which is responsible for its overall supervision and enforced by State Government through its Food and Drug Administration (FDA). Trade names are regulated by the Trade and Merchandise Marks Act (TMMA).

Gajaria points out that though “Branding exercises for pharma products in India do not have any specified guidelines, there are regulations for marketing.” The industry is mostly self-regulated with industry organisations formulating guidelines, which again impact only their members.

Giving more details Chatterjee reveals that,“The Drug and Magic Remedies (Objectionable Advertisement) Act mentions a list of ailments for which no advertising is permitted. The DCG(I), in collaboration with the OTC committee of the Organisation of Pharmaceutical Products of India (OPPI) has also decided that OTC advertisements for categories like digestives, antacids, cough liquids, vitamins tonic/cap, analgesic/ cold tabs, antiseptic creams, glucose powders, band-aids, baby gripe water, medicated skin products can be broadcast on TV.”

Chakraborty shares his expert knowledge on advertisement ethics saying, “Safety is a major concern when the FDA considers reclassifying a prescription drug as OTC. Most OTC drugs—unlike health foods, dietary supplements including medicinal herbs and complementary therapies -have been studied scientifically and extensively. However, all drugs have benefits and risks, and some degree of risk has to be tolerated, if people are to receive a drug's benefits. Defining an acceptable degree of risk is a judgement call. Labels on OTC drugs, which are required by the FDA, can help people understand a drug's benefits and risks as well as how to use the drug correctly. Often, the labels of OTC drugs do not list the full range of possible side effects, which is a cause of major concern as consumers may buy the drug on the basis of the brand name alone which may not necessarily be the appropriate medication for their ailment.”

Product branding for global markets is an entirely different ball game. There is a vast difference in the branding strategies for regulated and semi-regulated markets and hence no uniform strategy can be applied. Most regulated markets such as US and EU are highly commoditised or are gradually moving towards commodity generics. Hence, ‘product branding’ doesn’t have much role in these markets. Yet, despite these significant changes in the worldwide pharma market, the greatest advantage of such a branding exercise is its potential for improved financial performance. Global branding and shareholder value go hand in hand.

Chakraborty also reveals global regulatory practices saying,“The regulatory environment is becoming more standardised between countries. With the establishment of the European Medical Evaluations Agency (EMEA), which approves drugs for all the members of the EU, the borders are coming down. Japan has also adapted its approval system to facilitate the entry of Western products. And then there is direct to consumer (DTC) advertising. While doctors and healthcare professionals remain the targets for pharma marketing, companies are preparing for the spread of DTC and consumer-style branding beyond the shores of the US. The introduction of global branding anticipates the transition to a more consumer driven market.”

Das point outs, “The OTC branding and advertising guidelines are not very well laid out at the moment and will get defined over a period of time. With few product advertisements (i-Pill – CIPLA, Unwanted – Mankind, etc) having stirred up consumer groups and prominent doctors and individuals into action, it is only a matter of time before a guideline comes into place. Most advertisement and branding activities are highly individual company driven and will remain so in the future also.”

Das shows the benchmark of successful branding in India, “The focus on branding is getting higher as there is a general shift observed in the power of the consumer to directly take medication and seek alternatives when at the retailer's. The easy availability of information on various conditions also has helped expand the self medication market. Time constraints in meeting a doctor for minor ailments also leads to expansion of OTC sales. Pharma companies realise the importance of the change and are hence actively pursuing branding initiatives to expand business growth.”

Das admits that not many studies have been done to evaluate branding strategies conducted by companies. According to him, “The pressure of market competition and challenging targets push such studies to the back burner. The easiest way to evaluate impact of strategies is by monitoring internal sales performance and market share gain as reported by IMS. Marketing strategy of an organisation largely depends on product portfolio and is guided by the future directions set out in terms of segments and products of interest. The IFPMA (International Federation of Pharmaceutical Manufacturers and Association) code is an excellent guideline set out for ethical medical marketing. The guideline will be suitable for all marketers who have focus primarily on the Doctors to generate prescription sales.”

“With severe pressure to contain costs, companies need to build brands to overcome these pressures, “opines Chakraborty. ” The mega mergers were a way to contain costs and find new products, yet big companies still need about five new blockbuster products each year to return the promised growth. Companies need to get their marketing right, and get it right sooner rather than later, and global branding cuts marketing costs and allows a much faster and higher profile roll-out. There are more similarities than differences in attitudes between countries. Providing you do your market research properly, global advertising – the best way to establish global branding – will finally be possible,” he says . Shah however makes an important point hen he concludes , “Branding and marketing would most certainly help a company to go a long way However sustainable and profitable growth would largely come from continuous focus on quality.”

urgent vacancy at KAPL

Deasr friends,

It is encouraging proposal we received today from KAPL, Location : New Delhi,

They need fresh & experienced B.Pharm(Ayu), M.Pharm(Ayu),

PLZ NOTE: ***ALLTHE JOB SEEKING CANDIDATES including FRESH B.Pharm(AYU) & M.Pharm(AYU) ,send your consent with your updated resumes,

***IT IS SORRY TO NOTE THAT VERY FEW M.PHARM SCHOLARS HAVE SUBMITTED THEIR RESUMES, IN FACT THEY SHOULD LEAD THIS POSITIVELY

***WE WILL FORWARD ONLY THOSE NAMES WHOSE CONSENT & RESUMES WE RECEIVED,

***WE HOPE ALL OF YOU KNOW & UNDERSTAND THE EFFORTS WE ARE PUTTING IN FOR THIS PLACEMENT ,

***SO, WE SOLICIT YOUR YOUR GENEROUS FOLLOW UP AND ENTHUSIASM,